This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study sample
No power calculations were used to determine the sample size. Before chemotherapy, the patients were randomised to either group I (rhG-CSF) or group II (CAB). Forty patients were included in the study, 18 were randomised to group I while 22 were randomised to group II. Seven patients allocated to group II were excluded from the analysis as they switched to rhG-CSF. Three of these patients stopped treatment due to disease progression or death from the disease.
Study design
The study was a prospective randomised controlled trial that was carried out in a single centre. The method of randomisation was not reported. In addition, the authors did not report how the study sample was selected. The duration of follow-up was not stated. However, leucocyte counts were performed before the course and once between days 10 and 14 after the start of the course. Three patients died in the course of treatment.
Analysis of effectiveness
The analysis of the clinical study appears to have been conducted on the basis of treatment completers only, although this was not explicitly stated. The primary outcomes were the reduction in FL and the number of hospital days. FL was defined as a leucocyte count of less than 1.0 x10^9/L (grade IV on WHO toxicity scale) combined with fever (temperature higher than 38.5 degrees C), and was followed by hospitalisation and standard analyses of possible infectious foci. Patients were discharged when the temperature was normalised (lower than 37.5 degrees C for at least 24 hours) and when the leucocyte count was above 1.0 x10^9/L. The characteristics of the patients (age, metastases and metastatic sites) in the two groups appear to have been comparable.
Effectiveness results
Seven patients in group I (n=18) were hospitalised after 10 of the 108 courses for FL. Seven patients in group II (n=22) were hospitalised after 7 of the 98 courses, (p = non significant).
Before 5-FU dose reduction, 7 of 9 patients in group I and 6 of 13 patients in group II suffered from FL, after 54 (group I) and 49 (group II) courses, respectively, (p = non significant).
After 5-FU dose reduction for the last 18 patients studied (9 in each group), FL declined equally in both groups. There were no patients in group I suffering from FL and only one patient in group II.
The median hospital duration was 6 days (range: 5 -9) for group I and 7 days (range: 5 -10) for group II (p = non significant).
No infection-relation death was observed.
Twenty-two (20%) of the 108 courses received in group I were followed by grade IV leucopenia, compared with 41 (42%) of the 98 courses received in group II, (p<0.0025).
Grade IV leucopenia was followed by fever in 10 (45%) of the 22 courses received in group I, compared with 7 (17%) of the 41 courses received in group II, (p<0.025)
Clinical conclusions
The authors concluded that the results showed no significant difference in the incidence of hospitalisation due to FL between the two groups. However, in the group receiving CAB, a larger number of patients appear to have been at risk of developing fever with a significantly higher incidence of grade IV leucopenia. The authors noted that, although the reduction in the dosage of 5-FU affected the overall incidence of FL, this did not result in a significant difference in FL between the groups.
Measure of benefits used in the economic analysis
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No summary measure of benefit was derived. The study was therefore classified as a cost-consequences analysis.
Direct costs
Discounting was carried out, which was appropriate given that the costs were incurred during one hospitalisation period.
The cost boundary of the health service provider was adopted. The quantities measured comprised the number of days spent in hospital and the medications (CAB and rhG-CSF) used. It was unclear whether the quantities and costs were estimated using actual data gathered during the study or from another source. The source of the costs was a study conducted in the authors' institution, while medication costs were derived from wholesale prices. No dates were reported.
Statistical analysis of costs
The costs were treated in a stochastic manner. The costs were analysed using the Mann-Whitney U test, where p-values of less than or equal to 0.05 were considered significant.
Indirect Costs
The indirect costs were not included.
Currency
US dollars ($).
Sensitivity analysis
No sensitivity analyses were undertaken.
Estimated benefits used in the economic analysis
No summary measure of benefit was derived. See the 'Effectiveness Results' section.
Cost results
No difference was found between the groups in terms of regular oncology care and additional costs. The median cost per hospitalisation was $2,774 (range: 2,410 -3,866) in group I and $3,138 (range: 2,410 -4,230) in group II. The pvalues were not reported for the cost results.
The costs of antibiotic treatment were also comparable, median $332 (range: 40 -734) in group I versus median $439 (range: 108 -594) in group II.
The costs of rhG-CSF ($1,085 per course) were 6.6 times higher than CAB ($164 per course).
Synthesis of costs and benefits
The costs and benefits were not combined.
